| Ocu-labs, Inc. | |
| 7851 Metro Pkwy, Ste 225, Bloomington, Minnesota 55425 | |
| (952) 854-6702 |
| Name | Ocu-labs, Inc. |
|---|---|
| Organization Name | Ocu-labs Inc |
| Location | 7851 Metro Pkwy, Ste 225, Bloomington, Minnesota 55425 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (952) 854-6702 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
Early Homo sapiens had thick bone brows, this made raising eyebrows and a host of other facial expressions difficult for them. With passage of time evolution took its course and the brows smoothened.
Merck, known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes.
ATS Automation Tooling Systems Inc.has announced it has received a US $3.8 million (CDN $5.0 million) order from one of the world's largest pharmaceutical companies to provide a manufacturing system for a new drug delivery technology.
The Center for Global Health Policy's "Science Speaks" blog outlines efforts to fight TB/HIV co-infection in Zambia and Zimbabwe.
In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).
› Verified 8 days ago
| NPI Number | 1366443145 |
| Organization Name | OCU LABS INC |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 7851 Metro Pkwy, Suite 225, Bloomington, MN 55425 |
| Phone Number | 952-854-6702 |
News Archive
Early Homo sapiens had thick bone brows, this made raising eyebrows and a host of other facial expressions difficult for them. With passage of time evolution took its course and the brows smoothened.
Merck, known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes.
ATS Automation Tooling Systems Inc.has announced it has received a US $3.8 million (CDN $5.0 million) order from one of the world's largest pharmaceutical companies to provide a manufacturing system for a new drug delivery technology.
The Center for Global Health Policy's "Science Speaks" blog outlines efforts to fight TB/HIV co-infection in Zambia and Zimbabwe.
In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).
› Verified 8 days ago
News Archive
Early Homo sapiens had thick bone brows, this made raising eyebrows and a host of other facial expressions difficult for them. With passage of time evolution took its course and the brows smoothened.
Merck, known as MSD outside the United States and Canada, today announced Phase IIb data for MK-3102, the company's investigational once-weekly DPP-4 inhibitor in development for the treatment of type 2 diabetes.
ATS Automation Tooling Systems Inc.has announced it has received a US $3.8 million (CDN $5.0 million) order from one of the world's largest pharmaceutical companies to provide a manufacturing system for a new drug delivery technology.
The Center for Global Health Policy's "Science Speaks" blog outlines efforts to fight TB/HIV co-infection in Zambia and Zimbabwe.
In its November meeting, the Pharmaceutical Benefits Advisory Committee (PBAC) will consider Novo Nordisk's second-to-market glucagon-like peptide-1 (GLP-1) agonist Victoza for reimbursement, which would be essential in order for the drug to compete effectively with Eli Lilly's Byetta. However, its chances of success are uncertain, considering that it took three years to get Byetta on the Pharmaceutical Benefits Scheme (PBS).
› Verified 8 days ago
Cvs Pharmacy #03060 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 8936 Lyndale Ave S, Bloomington, Minnesota 55420 Phone: (952) 881-0163 | |
Cvs Pharmacy #16002 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2555 W 79th St, Bloomington, Minnesota 55431 Phone: (952) 888-4677 | |
Bloomington Drug Type: Community/Retail Pharmacy Location: 509 W 98th St, Bloomington, Minnesota 55420 Phone: (952) 884-7528 | |
Cub Pharmacy #1931 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 500 W 84th St, Bloomington, Minnesota 55420 Phone: (952) 346-8625 | |
Cub Pharmacy #1950/790 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 10520 France S Ave, Bloomington, Minnesota 55431 Phone: (952) 888-4310 |